The Money Behind the MDMA Resubmission Came From a SpaceX Director
In August we reported that MDMA assisted therapy had gone back to the FDA without a new phase 3 trial. The obvious question was who would fund that gamble after the agency rejected the first application. The Wall Street Journal answered it on September 5. A director at SpaceX wrote a 25 million dollar check.
Who funds a therapy shapes how fast it arrives and what it costs on the other end. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| Who | Antonio Gracias and Steve Jurvetson, SpaceX directors and allies of Elon Musk |
| The rescue | Gracias gave 25 million dollars from his family foundation to recapitalize Lykos Therapeutics |
| What changed | Lykos was renamed Resilient Pharmaceuticals and moved to Chicago, beside his investment firm |
| The academic money | A 16 million dollar Harvard endowment for a professorship on psychedelics in society and culture |
| Others involved | Kimbal and Christiana Musk funded research including an academic fellowship |
| Why it matters | Philanthropic capital has different patience than venture capital, and it shows in the strategy |
The Check That Restarted the Application
The FDA rejected the Lykos application for MDMA assisted therapy in 2024. The company went into a financial tailspin. We covered what that rejection meant at the time in our look at the FDA ruling.
Antonio Gracias then cut a 25 million dollar check from his family foundation to recapitalize it. He renamed the company Resilient Pharmaceuticals and moved its headquarters to Chicago.
Chicago is also home to Valor Equity Partners, his investment firm. Resilient is now in talks to raise additional funding and has resubmitted its new drug application.
Why That Explains the Strategy
This is the part worth sitting with. A venture fund has a return horizon and limited partners. A family foundation does not.
That difference explains a decision that looked strange in August. Going back to the FDA without a new phase 3 is a poor risk-adjusted bet for money that needs an exit. It is defensible for money trying to move a field. We laid out that gamble in our coverage of the resubmission.
Patient capital changes what a company can attempt. It does not change what the FDA requires.
The Rejection Was Not Procedural
The original application drew criticism for missing serious adverse events in some study subjects, including suicidal thoughts. That is the substance behind the rejection.
New funding does not address that. Nor does a new corporate name or a new city.
The resubmission still has to satisfy the agency on the questions that sank it. Reporting a rescue is not the same as reporting a fix.
The Academic Money Is a Separate Play
Gracias also endowed a Harvard program with 16 million dollars. It funds a professorship and research on psychedelics in society and culture.
Read that description closely. It is not a clinical trial. It funds the study of how psychedelics sit in culture, which is narrative infrastructure rather than evidence.
Kimbal Musk, a Tesla director, and Christiana Musk have funded research including an academic fellowship. Steve and Genevieve Jurvetson previously funded the Lykos trials, and she serves on the board of a psychedelic philanthropy nonprofit.
This Is a Different Kind of Capital
The psychedelic industry has spent two years being described through pharmaceutical dealmaking. Lilly bought AtaiBeckley, as we covered in the largest psychedelic acquisition yet. Big pharma entered the race in earnest.
This is not that. These are personal fortunes made in aerospace and electric vehicles, deployed through family foundations rather than funds.
The people writing these checks have no clinical background and no fiduciary duty to anyone. That is a strength for tolerating risk and a weakness for external scrutiny.
What It Means Downstream
For clinics, the near-term effect is nothing. MDMA remains federally illegal and unapproved, and a resubmission is not an approval.
The longer-term effect is that approval timelines become less dependent on whether the science looks like a good investment. A field funded philanthropically can survive rejections that would end a venture-backed company.
That cuts both ways. It keeps promising work alive. It also keeps applications alive that the market would have retired.
The Bottom Line
The useful fact here is not that wealthy people like psychedelics. It is that the capital base behind MDMA approval is philanthropic. It sits with a handful of connected families.
That is worth knowing when reading the next announcement about progress. Ask who is funding it and what that money needs back. The same question applies to the product design choices driving the rest of the field.
Patients looking for supervised care can start with our directory of verified ketamine clinics.
This article is for informational purposes and is not medical or investment advice. MDMA remains a Schedule I substance under federal law and is not an approved treatment.
